Preclinical investigation of the safety of eplir

A. S. Saratikov, N. S. Livshits, F. I. Burchenkova, N. G. Kadychagova, T. P. Novozheeva, R. R. Akhmedzhanov, T. V. Perevozchikova, L. V. Bashirova

Результат исследований: Материалы для журналаСтатья

Аннотация

The preclinical toxicological evaluation of eplir, a new hepatoprotective drug, has been performed. It was established that, in terms of the acute toxicity parameters, eplir is a low-toxicity substance. A six-month peroral administration of the drug in a dose of 30, 150, and 300 mg/kg in rats and 100 mg/kg in dogs did not cause any substantial functional and structural disorders in the organs and systems of the experimental animals. Eplir does not possess mutagenic, carcinogenic, allergenic, and immunotoxic properties and does not affect the reproductive function.

Язык оригиналаАнглийский
Страницы (с-по)64-66
Число страниц3
ЖурналPharmaceutical Chemistry Journal
Том39
Номер выпуска2
DOI
СостояниеОпубликовано - 1 фев 2005

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Цитировать

Saratikov, A. S., Livshits, N. S., Burchenkova, F. I., Kadychagova, N. G., Novozheeva, T. P., Akhmedzhanov, R. R., Perevozchikova, T. V., & Bashirova, L. V. (2005). Preclinical investigation of the safety of eplir. Pharmaceutical Chemistry Journal, 39(2), 64-66. https://doi.org/10.1007/s11094-005-0082-3